Bristol-Myers Squibb Co (BMY)
44.70
-4.16
(-8.51%)
USD |
NYSE |
Apr 25, 16:00
44.74
+0.04
(+0.09%)
Pre-Market: 08:01
Bristol-Myers Squibb Cash from Financing (Quarterly): 967.00M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 967.00M |
September 30, 2023 | -5.16B |
June 30, 2023 | -2.173B |
March 31, 2023 | -3.05B |
December 31, 2022 | -3.246B |
September 30, 2022 | -4.543B |
June 30, 2022 | -3.52B |
March 31, 2022 | -5.653B |
December 31, 2021 | -3.967B |
September 30, 2021 | -1.78B |
June 30, 2021 | -3.182B |
March 31, 2021 | -7.295B |
December 31, 2020 | 3.483B |
September 30, 2020 | -2.587B |
June 30, 2020 | -993.00M |
March 31, 2020 | -1.054B |
December 31, 2019 | -7.677B |
September 30, 2019 | -941.00M |
June 30, 2019 | 18.27B |
March 31, 2019 | -2.029B |
December 31, 2018 | -578.00M |
September 30, 2018 | -720.00M |
June 30, 2018 | -1.015B |
March 31, 2018 | -1.222B |
December 31, 2017 | -1.352B |
Date | Value |
---|---|
September 30, 2017 | -706.00M |
June 30, 2017 | -1.006B |
March 31, 2017 | -1.013B |
December 31, 2016 | -605.00M |
September 30, 2016 | -546.00M |
June 30, 2016 | -552.00M |
March 31, 2016 | -950.00M |
December 31, 2015 | -1.359B |
September 30, 2015 | -700.00M |
June 30, 2015 | -883.00M |
March 31, 2015 | -682.00M |
December 31, 2014 | -231.00M |
September 30, 2014 | -528.00M |
June 30, 2014 | -486.00M |
March 31, 2014 | -1.192B |
December 31, 2013 | 711.00M |
September 30, 2013 | -620.00M |
June 30, 2013 | -1.115B |
March 31, 2013 | -44.00M |
December 31, 2012 | -958.00M |
September 30, 2012 | -1.689B |
June 30, 2012 | -850.00M |
March 31, 2012 | -836.00M |
December 31, 2011 | -754.00M |
September 30, 2011 | -704.00M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-7.677B
Minimum
Dec 2019
18.27B
Maximum
Jun 2019
-1.795B
Average
-3.05B
Median
Mar 2023
Cash from Financing (Quarterly) Benchmarks
Amgen Inc | 2.754B |
Gilead Sciences Inc | -1.099B |
Johnson & Johnson | -4.655B |
Karuna Therapeutics Inc (DELISTED) | 19.87M |
2seventy bio Inc | 0.253M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | 4.252B |
Cash from Investing (Quarterly) | -1.346B |
Free Cash Flow | 12.65B |
Free Cash Flow Per Share (Quarterly) | 1.929 |
Free Cash Flow to Equity (Quarterly) | 1.754B |
Free Cash Flow to Firm (Quarterly) | 4.255B |
Free Cash Flow Yield | 13.62% |